Novan Therapeutics announces positive trial results for acne treatment

Posted by David Bracken on March 19, 2014 

Novan Therapeutics, a Durham company that is developing nitric oxide-based skin therapies, announced Wednesday positive Phase 2 clinical trial results for its acne therapy.

“The results from this Phase 2 study exceeded our expectations,” said Nate Stasko, Novan’s president, in a statement. “This data enables us to move forward with late stage clinical development for a fast acting, first-in-class new drug for acne.”

Novan began operations in January 2008 and has raised $20 million in private equity funding from individuals. The company has no drugs on the market.

In August, the company was awarded a $7.8 million government contract to develop a treatment for thermal burns. Novan's technology allows for the delivery of nitric oxide in controlled amounts for the treatment of different skin diseases and injuries.

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service